Company intelligence / Profile preview

Xanadu Bio

Gladwyne, Pennsylvania, United Statesxanadubio.com ↗
Ownership
Private
Development stage
Other
01

Overview

Xanadu Bio’s PACE polymer nanoparticle platform is designed to deliver mRNA and other nucleic acid payloads; they have demonstrated robust preclinical delivery in oncology, immunology, and mucosal immunity applications, including nasal vaccines for respiratory pathogens

Therapeutic areas
OncologyInfectious DiseasesImmunology
Modalities
mRNA-based drugsPolymer nanoparticle delivery therapyRNA therapy
Industry
Biotech
02

Drug pipeline

11 assets

XPACE-2003

Preclinical

10 more assets in the full pipeline.

03

Partnerships

Yale University

Beyond the preview

Go deeper on Xanadu Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Xanadu Bio.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call